Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

RHINO: An Integrative Multi-Omics Framework Linking Circadian Physiology to Precision Medicine.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026

Same author

A Bayesian Adaptive Marker-Stratified Design for Phase II Clinical Trials Using Calibrated Spike-and-Slab priors.

Statistics in biopharmaceutical research·2026

Same author

An Adaptive Biomarker-based Umbrella Trial Design Using Bayesian Latent Class Model.

Statistics in biopharmaceutical research·2026

Same author

Histone deacetylase enzyme activity is not the universal anticancer target of HDAC inhibitors.

Signal transduction and targeted therapy·2026

Same author

Modeling context-dependent RNA splicing by deep learning.

Nature computational science·2026

Same author

A retrospective pharmacovigilance analysis based on the FAERS database reveals sex-associated differences in toxicities of CAR T-cell therapy.

Nature communications·2026

Search research articles

Related Experiment Video

Updated: May 16, 2025

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

A model-free phase I/II dose optimization design for immunotherapy trials.

Yingjie Qiu¹, Mengyi Lu², Yan Han³

¹Peter O'Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dallas, TX, USA.

Statistical Methods in Medical Research

|May 15, 2025

Summary

This summary is machine-generated.

We developed a new, model-free clinical trial design called the UFO design to optimize immunotherapy dosage. This approach efficiently models toxicity, efficacy, and immune responses for better treatment outcomes.

Keywords:

Phase I/II clinical trials admissible set delayed outcomes dose optimization immunotherapy isotonic regression model-free utility

More Related Videos

A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research

A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research

Published on: August 15, 2019

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors

Published on: December 16, 2022

Related Experiment Videos

Last Updated: May 16, 2025

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research

A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research

Published on: August 15, 2019

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors

Published on: December 16, 2022

Area of Science:

Clinical Trials
Immunotherapy
Biostatistics

Background:

Optimizing immunotherapy dosage is crucial for maximizing efficacy while minimizing toxicity.
Existing clinical trial designs often rely on complex parametric models, limiting transparency and efficiency.
Jointly modeling multiple outcomes like toxicity, efficacy, and immune response is challenging but essential for immunotherapy dose optimization.

Purpose of the Study:

To introduce a novel, model-free phase I/II clinical trial design (UFO design) for optimizing immunotherapy dosage.
To enable efficient information sharing across dose levels by leveraging correlations between toxicity, efficacy, and immune response.
To extend the UFO design to accommodate delayed outcome data and demonstrate its favorable operating characteristics.

Main Methods:

Developed a model-free approach for clinical trial design, termed the UFO design.
Utilized inherent correlations among toxicity, efficacy, and immune response outcomes.
Incorporated constrained dose-outcome ordering to facilitate information sharing.
Extended the design to handle delayed outcomes.

Main Results:

The UFO design demonstrated efficiency and transparency for clinical implementation.
Simulation studies showed favorable operating characteristics for the proposed design.
The model-free approach effectively optimizes immunotherapy dosage by jointly modeling multiple outcomes.

Conclusions:

The UFO design offers a practical and effective model-free strategy for optimizing immunotherapy dosage in clinical trials.
This approach enhances efficiency and transparency by leveraging outcome correlations and dose-outcome constraints.
The availability of an R Shiny app facilitates the simulation and implementation of the UFO design in practice.